Irbesartan + Hidroclorotiazida Ciclum

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Ciclum, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Irbesartan + Hidroclorotiazida Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, provides batch‑to‑batch consistency, and offers reliable logistics for global distribution. Customers benefit from responsive technical support and regulatory assistance throughout the procurement process.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin system and renal sodium handling to control high blood pressure.

- Hypertension: reduces systolic and diastolic pressure in patients with essential hypertension. - Hypertension with edema: assists in fluid‑overload management while lowering blood pressure. - Hypertension in type 2 diabetes: provides blood pressure control with added renal protective benefits.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium or sodium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration - Hyperkalemia - Acute kidney injury - Angioedema - Severe hypotension - Allergic skin reactions

When prescribing Irbesartan/Hydrochlorothiazide, clinicians should observe several safety considerations.

- Monitor blood pressure: ensure target levels are achieved without excessive drop. - Assess renal function: check serum creatinine and eGFR before and during therapy. - Evaluate electrolytes: watch for potassium and sodium abnormalities. - Use caution in elderly: increased sensitivity to blood‑pressure changes. - Avoid in severe hepatic impairment: limited safety data. - Store at room temperature: keep in original packaging, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use may increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity risk. - ACE inhibitors or other ARBs: additive effects on blood pressure and potassium. - High‑dose NSAIDs: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may cause additive hypotension, dose adjustment needed. - CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma levels. - Antidiabetic drugs: diuretic‑induced changes in glucose may require dose modification. - Regular‑dose NSAIDs: monitor renal function and electrolytes. - Antacids containing aluminum/magnesium: may affect absorption of hydrochlorothiazide.